UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnosing Cystic Fibrosis in Adults

Seminars in respiratory and critical care medicine, 2023-04, Vol.44 (2), p.242-251

2023

Volltextzugriff (PDF)

Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil

BMC pulmonary medicine, 2020-07, Vol.20 (1), p.194-194, Article 194

2020

Volltextzugriff (PDF)

Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease

Chest, 2014-07, Vol.146 (1), p.152-158

2014

Volltextzugriff (PDF)

Assessing the health risk of living near composting facilities on lung health, fungal and bacterial disease in cystic fibrosis: a UK CF Registry study

Environmental health, 2022-12, Vol.21 (1), p.130-130, Article 130

2022

Volltextzugriff (PDF)

Cystic fibrosis modulator therapy can reverse cystic bronchiectasis

Respirology case reports, 2023-07, Vol.11 (7), p.e01172-n/a

2023

Volltextzugriff (PDF)

Introducing the Adult Cystic Fibrosis Series: An Exciting Time of Change, But New Challenges Lie Ahead

Chest, 2021-01, Vol.159 (1), p.3-4

Simmonds, Nicholas J

2021

Volltextzugriff (PDF)

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

Trials, 2021-08, Vol.22 (1), p.578-578, Article 578

2021

Volltextzugriff (PDF)

Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape

Chest, 2021-01, Vol.159 (1), p.93-102

2021

Volltextzugriff (PDF)

Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

The European respiratory journal, 2024-09, Vol.64 (3), p.2400929

2024

Volltextzugriff (PDF)

New strategies of physical activity assessment in cystic fibrosis: a pilot study

BMC pulmonary medicine, 2020-10, Vol.20 (1), p.1-285, Article 285

2020

Volltextzugriff (PDF)

Clinimetric analysis of outcome measures for airway clearance in people with cystic fibrosis: a systematic review

Therapeutic Advances in Respiratory Disease, 2022, Vol.16, p.17534666221122572

2022

Volltextzugriff (PDF)

Why don't anti-inflammatories work in cystic fibrosis?

Expert review of respiratory medicine, 2024-02, Vol.18 (1-2), p.1-3

2024

Volltextzugriff (PDF)

Is daily physical activity affected by dynamic hyperinflation in adults with cystic fibrosis?

BMC pulmonary medicine, 2018-04, Vol.18 (1), p.60-60, Article 60

2018

Volltextzugriff (PDF)

Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial

BMJ open respiratory research, 2020-10, Vol.7 (1), p.e000694

2020

Volltextzugriff (PDF)

The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK

Scientific reports, 2020-06, Vol.10 (1), p.10660-10660, Article 10660

2020

Volltextzugriff (PDF)

Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden

Chest, 2022-12, Vol.162 (6), p.1241-1254

2022

Volltextzugriff (PDF)

The Man in the Paper Mask: One (Mask) for All and All for . . . Cystic Fibrosis?

American journal of respiratory and critical care medicine, 2018-02, Vol.197 (3), p.281-283

2018

Volltextzugriff (PDF)

Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis

Journal of cystic fibrosis, 2019-05, Vol.18 (3), p.420-424

2019

Volltextzugriff (PDF)

Entering the era of highly effective modulator therapies

Pediatric pulmonology, 2021-02, Vol.56 (S1), p.S79-S89

2021

Volltextzugriff (PDF)

How representative are clinical trial cohorts of the general CF population? Implications for trial planning

Journal of cystic fibrosis, 2024-01, Vol.23 (1), p.68-72

2024

Volltextzugriff (PDF)

Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study

Journal of cystic fibrosis, 2022-03, Vol.21 (2), p.302-308

2022

Volltextzugriff (PDF)

The effectiveness of CFTR modulators in people with CF and rare mutations: A real‐world study

Pediatric pulmonology, 2024-01, Vol.59 (1), p.221-224

2024

Volltextzugriff (PDF)

Mediation of the total effect of cystic fibrosis‐related diabetes on mortality: A UK Cystic Fibrosis Registry cohort study

Diabetic medicine, 2022-11, Vol.39 (11), p.e14958-n/a

2022

Volltextzugriff (PDF)

Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials

Journal of cystic fibrosis, 2019-09, Vol.18 (5), p.e45-e46

2019

Volltextzugriff (PDF)

Hot off the breath: ‘I've a cost for’—the 64 million dollar question

Thorax, 2012-05, Vol.67 (5), p.382-384

2012

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(183)

Publikationsform

Artikel
(117)
Buchkapitel
(72)
Bücher
(1)
Berichte
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Diagnosing Cystic Fibrosis in Adults

Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil

Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease

Assessing the health risk of living near composting facilities on lung health, fungal and bacterial disease in cystic fibrosis: a UK CF Registry study

Cystic fibrosis modulator therapy can reverse cystic bronchiectasis

Introducing the Adult Cystic Fibrosis Series: An Exciting Time of Change, But New Challenges Lie Ahead

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape

Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

New strategies of physical activity assessment in cystic fibrosis: a pilot study

Clinimetric analysis of outcome measures for airway clearance in people with cystic fibrosis: a systematic review

Why don't anti-inflammatories work in cystic fibrosis?

Is daily physical activity affected by dynamic hyperinflation in adults with cystic fibrosis?

Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial

The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK

Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden

The Man in the Paper Mask: One (Mask) for All and All for . . . Cystic Fibrosis?

Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis

Entering the era of highly effective modulator therapies

How representative are clinical trial cohorts of the general CF population? Implications for trial planning

Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study

The effectiveness of CFTR modulators in people with CF and rare mutations: A real‐world study

Mediation of the total effect of cystic fibrosis‐related diabetes on mortality: A UK Cystic Fibrosis Registry cohort study

Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials

Hot off the breath: ‘I've a cost for’—the 64 million dollar question

Suchergebnisse filtern